Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.50 |
| ▸ | MMP9 | P14780 | 15/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958790 | 0.79 | MMP2 (0.70) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| SCHEMBL7370003 | 0.77 | MMP2 (0.72) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| SCHEMBL6888752 | 0.76 | MMP2 (0.44) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| Trifluoroacetic Acid SCHEMBL4958585 | 0.75 | MMP2 (0.64) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| SCHEMBL14271497 | 0.72 | MMP2 (0.62) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| SCHEMBL6500230 | 0.71 | MMP2 (0.61) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL383079 | 0.71 | MMP2 (0.61) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| Trifluoroacetic Acid SCHEMBL7649357 | 0.71 | MMP2 (0.65) | MMP2MMP9ADAMTS4MMP13MMP1 | |
| Hydrochloric Acid SCHEMBL7336920 | 0.70 | MMP2 (0.59) | MMP2MMP9ADAMTS4MMP13ADAMTS5 | |
| Hydrochloric Acid SCHEMBL382133 | 0.70 | MMP2 (0.59) | MMP2MMP9ADAMTS4MMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296678-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |